Published on 23 Nov 2022 on Zacks via Yahoo Finance
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
Glaukos Corporation GKOS is well-poised for growth, backed by favorable clinical trial results and a robust product pipeline. However, stiff competition remains a concern.
Shares of this Zacks Rank #3 (Hold) have gained 6.3% against the industry’s decline of 29.2% on a year-to-date basis. The S&P 500 Index has fallen 18.3% in the same time frame.
Glaukos — with a market capitalization of $2.25 billion — is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 16.3% for 2023 and expects to sustain its strong performance. The company has a trailing negative four-quarter earnings surprise of 7.6%, on average.